AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs

AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs

The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest's reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern Medical University to share insights from the AASLD and discuss the work presented by his team at the conference, along with their learning experiences.
Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting was grandly held in Boston, USA. In this event, Dr. Wen Xie's team from Beijing Ditan Hospital, Capital Medical University, presented several notable research findings. One of them is a study on the stability of decompensation in patients with chronic hepatitis B and liver cirrhosis treated with entecavir (ETV) [1], which received the Outstanding Abstract Award at the conference. Hepatology Digest reports on these research findings as follows.
AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention

AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention

The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest's reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern Medical University to share insights from the AASLD and discuss the work presented by his team at the conference, along with their learning experiences.
AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

The 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) has just concluded in Boston, USA. The team led by Professor Wai-Kay Seto from the University of Hong Kong focused on five research outcomes in the areas of mother-to-child transmission blockage and clinical cure of Hepatitis B, clearance of Hepatitis C, post-operative recurrence of liver cancer, and post-liver transplant management. These outcomes were presented at the meeting, with two of them being shared in the form of oral presentations. Professor Seto's team has been committed to the clinical management and scientific research of chronic liver diseases, achieving fruitful results. Hepatology Digest invited the team's principal researchers to interpret the findings and comment on the trends in liver disease research and share their experiences at the conference. The interview video is shared below.
Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.
Doctor Philippa Easterbrook: WHO to Release New Hepatitis B Guidelines, Focusing on Expanding Treatment Eligibility and Simplifying Diagnosis and Treatment Pathways

Doctor Philippa Easterbrook: WHO to Release New Hepatitis B Guidelines, Focusing on Expanding Treatment Eligibility and Simplifying Diagnosis and Treatment Pathways

At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL 2023) and EASL Congress 2023, Doctor Philippa Easterbrook, Senior Scientist at the Global Hepatitis Programme of the Department of HIV at the World Health Organization (WHO) headquarters in Geneva, attended the WHO-ECDC Joint Forum. She discussed the new directions being drafted in WHO's updated Hepatitis B guidelines, focusing on expanding simplified treatment criteria, service delivery, and innovative diagnostics. Hepatology Digest had the privilege to interview Doctor Philippa Easterbrook about WHO's 2030 goals, the progress of the new Hepatitis B guidelines, essential information, and the global challenges and opportunities in addressing Hepatitis B prevention and control.
EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.